Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Ali Albenmousa"'
Autor:
Saleh A. Alqahtani, Dieter C. Broering, Saad A. Alghamdi, Khalid I. Bzeizi, Noara Alhusseini, Saleh I. Alabbad, Ali Albenmousa, Nasreen Alfaris, Faisal Abaalkhail, Waleed K. Al-hamoudi
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Several trend analyses on liver transplantation (LT) indications have been published in the U.S. and in other countries, but there are limited data on LT indication trends in Saudi Arabia (SA), especially since the availability of
Externí odkaz:
https://doaj.org/article/4ff09a5d27bc410ab9292c1042cb481b
Publikováno v:
Annals of Hepatology, Vol 18, Iss 3, Pp 439-444 (2019)
Introduction and aim: Autoimmune hepatitis (AIH) may present acutely, which can rapidly progress to fulminant type. This pattern has been described worldwide but is generally under-reported. We aim to describe the clinical presentation and treatment
Externí odkaz:
https://doaj.org/article/52b374dd730644b586f74f3f24752c85
Autor:
Dieter Broering, Mohamed Shawkat, Ali Albenmousa, Faisal Abaalkhail, Saleh Alabbad, Waleed Al-Hamoudi, Saad Alghamdi, Saleh Alqahthani, Ahmad Jaafari, Roberto Troisi, Khalid Bzeizi
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251487 (2021)
IntroductionHepatic steatosis (HS) negatively impacts transplant outcomes in living liver donors. To date, liver biopsy is preferred for HS evaluation. This study aims to evaluate the measurement of controlled attenuation parameter (CAP) as a diagnos
Externí odkaz:
https://doaj.org/article/562cc6dc058f45cbb183915d3b4a4d78
Autor:
Khalid I. Bzeizi, Mohammad Arabi, Negar Jamshidi, Ali Albenmousa, Faisal M. Sanai, Waleed Al-Hamoudi, Saad Alghamdi, Dieter Broering, Saleh A. Alqahtani
Publikováno v:
Cancers, Vol 13, Iss 24, p 6172 (2021)
Hepatocellular carcinoma (HCC) occurs in nearly three-quarters of all primary liver cancers, with the majority not amenable to curative therapies. We therefore aimed to re-evaluate the safety, efficacy, and survival benefits of treating patients with
Externí odkaz:
https://doaj.org/article/f8f0aa9338914078a4c64e000d7fc01c
Autor:
Abdulrahman A Aljumah, Badr Al Jarallah, Ali Albenmousa, Abdullah Al Khathlan, Adnan Al Zanbagi, Mohammed Al Quaiz, Bandar Al-Judaibi, Khalid Nabrawi, Waleed Al Hamoudi, Mohammed Alghamdi, Hind Fallatah
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 24, Iss 7, Pp 1-20 (2018)
Externí odkaz:
https://doaj.org/article/468702f1c1f34f8da9fa757bb4eecda4
Autor:
Ahmed A. Al-Qahtani, Mashael R. Al-Anazi, Fahad A. Al-Zoghaibi, Ayman A. Abdo, Faisal M. Sanai, Waleed K. Al-Hamoudi, Khalid A. Alswat, Hamad I. Al-Ashgar, Mohammed Q. Khan, Ali Albenmousa, Hanif Khalak, Mohammed N. Al-Ahdal
Publikováno v:
Annals of Hepatology, Vol 15, Iss 6, Pp 824-833 (2016)
Background The protein encoded by PARK2 gene is a component of the ubiquitin-proteasome system that mediates targeting of proteins for the degradation pathway. Genetic variations at PARK2 gene were linked to various diseases including leprosy, typhoi
Externí odkaz:
https://doaj.org/article/bea38431ebaa400492a301587628e1df
Autor:
Ahmed A. Al-Qahtani, Mashael R. Al-Anazi, Nyla Nazir, Ayman A. Abdo, Faisal M. Sanai, Waleed K. Al-Hamoudi, Khalid A. Alswat, Hamad I. Al-Ashgar, Mohammed Q. Khan, Ali Albenmousa, Ahmed El-Shamy, Salah K. Alanazi, Damian Dela Cruz, Marie Fe F. Bohol, Mohammed N. Al-Ahdal
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 8 (2018)
Viral mutations acquired during the course of chronic hepatitis B virus (HBV) infection are known to be associated with the progression and severity of HBV-related liver disease. This study of HBV-infected Saudi Arabian patients aimed to identify ami
Externí odkaz:
https://doaj.org/article/a82823c7c6d64790950b6d0eef955594
Autor:
Ahmed Al-Qahtani, Mashael Al-Anazi, Ayman A. Abdo, Faisal M. Sanai, Waleed Al-Hamoudi, Khalid A. Alswat, Hamad I. Al-Ashgar, Mohammed Q. Khan, Ali Albenmousa, Nisreen Khalaf, Nisha Viswan, Mohammed N. Al-Ahdal
Publikováno v:
Journal of Immunology Research, Vol 2015 (2015)
Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients. The aim of the study was to correlate the serum level of IL28B in HCV
Externí odkaz:
https://doaj.org/article/bbd503c568b6439083da6e13e424986e
Autor:
Saad Alghamdi, Shaden Alamro, Dhari Alobaid, Elwy Soliman, Ali Albenmousa, Khalid Ibrahim Bzeizi, Saleh Alabbad, Saleh A Alqahtani, Dieter Broering, Waleed Al-Hamoudi
Publikováno v:
World Journal of Hepatology. 15:274-281
Autor:
Sabine Matou-Nasri, Hamad I. Al-Ashgar, Jahad Alghamdi, Khalid Alswat, Ahmed A. Al-Qahtani, Waleed Al-Hamoudi, Arwa A. Al-Qahtani, Mashael R. Al-Anazi, Mohammed Q. Khan, Marie Fe F. Bohol, Monis Bilal Shamsi, Ayman A. Abdo, Mohammed N. Al-Ahdal, Salah K. Alanazi, Faisal M. Sanai, Ali Albenmousa, Damian M. Dela Cruz
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-14 (2019)
Scientific Reports
Scientific Reports
Interleukin-37 (IL-37) has recently been recognized as a strong anti-inflammatory cytokine having anti-tumor activity against hepatocellular carcinoma (HCC) in hepatitis B virus (HBV)-infected patients. HCC is a typical inflammation-related cancer, a